Cataplexy Drug to be Used for Excessive Daytime Sleepiness (EDS)
Mar 22, 2005 - 8:59:00 AM
|
|
|
Sodium oxybate is currently marketed as the first and only approved treatment for cataplexy, a sudden loss of muscle tone, a debilitating symptom of narcolepsy. The sNDA is expected to expand the sodium oxybate label to include the reduction of excessive daytime sleepiness (EDS) and the improvement in fragmented nighttime sleep in narcolepsy patients.
|
By Akanksha, Pharmacology Correspondent,
[RxPG] Orphan Medical, Inc. has announced that the Food and Drug Administration (FDA) has accepted for filing the Company's Supplemental New Drug Application (sNDA) for Xyrem(R) (sodium oxybate) oral solution. The FDA also notified the Company that the review deadline per the PDUFA regulation is November 18, 2005.
Sodium oxybate is currently marketed as the first and only approved treatment for cataplexy, a sudden loss of muscle tone, a debilitating symptom of narcolepsy. The sNDA is expected to expand the sodium oxybate label to include the reduction of excessive daytime sleepiness (EDS) and the improvement in fragmented nighttime sleep in narcolepsy patients.
With approval of the sNDA, sodium oxybate would be the first medication approved to treat the primary symptoms of narcolepsy. Prior to approval of sodium oxybate, antidepressants were used off-label to treat cataplexy.
EDS has been treated with stimulant medications, and disrupted nighttime sleep by sedative-hypnotic medications. The sNDA includes two Phase III(b) trials with EDS as the primary efficacy measure, as well as positive data relating to the treatment of other components of narcolepsy. The sNDA was the Company's first submission in the electronic common technical document (eCTD) format now required by the FDA.
The FDA is expected to grant orphan drug status to the new indication when approved under the sNDA. Medical formulations with orphan drug designation that are the first approved for a particular indication obtain orphan drug status which confers seven years of market exclusivity from the approval date in the United States.
Orphan drugs are products that treat diseases affecting fewer than 200,000 U.S. patients. The FDA previously granted sodium oxybate orphan drug designation for narcolepsy, and upon its initial approval in 2002, sodium oxybate was awarded orphan drug status for cataplexy by the FDA.
Orphan Medical also announced that it has received a milestone fee of $1 million from UCB Pharma tied to submission of the sNDA in the United States. In addition, UCB Pharma has notified the Company that responses to questions by the European Medicines Evaluation Agency (EMEA) have been submitted for the agency's review. The next milestone fee due from UCB Pharma is associated with regulatory approval of sodium oxybate in Europe, and is expected before the end of 2005.
Nearly two-thirds of the 150 patients needed to satisfy the fibromyalgia proof-of-principle protocol have finished the trial. Orphan Medical expects to announce results of the trial in the third quarter of 2005. The protocol calls for patients to complete a three-month trial with an eight-week active treatment period that will assess the impact of sodium oxybate on the symptoms of fibromyalgia, including the sleep disturbance that typically accompanies fibromyalgia.
After a washout period, patients are randomly assigned to blinded treatment consisting of two active sodium oxybate dosing arms or to a placebo arm. Twenty centers located throughout the United States are participating in the trial.
Fibromyalgia is a chronic condition that is estimated to affect over four million individuals in the United States and represents a market opportunity in excess of $1 billion per year. The disease is characterized by widespread muscle pain and stiffness, and affects women three times more often than men. Other symptoms include persistent fatigue, headaches, cognitive or memory impairment, morning stiffness and non-restorative sleep.
Narcolepsy is a chronic, debilitating neurological disease whose primary symptoms are EDS, fragmented nighttime sleep and cataplexy. Cataplexy, a sudden loss of muscle tone, is usually triggered by strong emotions such as laughter, anger or surprise. All patients with narcolepsy suffer from EDS and an estimated 60 to 90 percent suffer from cataplexy. Patients often selectively isolate themselves from social interaction with others resulting in a worsening effect on a patient's quality of life.
Narcolepsy afflicts 100,000 to 140,000 Americans, of which an estimated 50,000 receive some form of treatment for their symptoms. The estimated total addressable narcolepsy market based on sodium oxybate pricing exceeds $250 million.
Publication:
Orphan Medical, Inc.
On the web:
Orphan 
|
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Pharmacology Newsletter
|
|
|
|
Additional information about the news article
|
Orphan Medical acquires, develops and markets pharmaceuticals of high medical value for inadequately treated and uncommon CNS diseases treated by specialist physicians. Xyrem has now been assessed as a treatment for the full range of narcolepsy symptoms including excessive daytime sleepiness. The Company is also conducting a trial to evaluate Xyrem as a treatment for symptoms of fibromyalgia syndrome.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
